Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Free Cash Flow (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Free Cash Flow for 15 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 26.18% to $3.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$698000.0, a 445.54% decrease, with the full-year FY2025 number at -$2.2 million, down 26.09% from a year prior.
  • Free Cash Flow was $3.7 million for Q4 2025 at Aytu Biopharma, up from -$618000.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $9.4 million in Q2 2023 to a low of -$9.1 million in Q1 2022.
  • A 5-year average of -$1.5 million and a median of -$1.1 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 2247.41% in 2024, then tumbled 2468.5% in 2025.
  • Aytu Biopharma's Free Cash Flow stood at -$8.8 million in 2021, then soared by 71.8% to -$2.5 million in 2022, then surged by 94.57% to -$135000.0 in 2023, then soared by 2247.41% to $2.9 million in 2024, then increased by 26.18% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Free Cash Flow are $3.7 million (Q4 2025), -$618000.0 (Q3 2025), and $2.8 million (Q2 2025).